Protara Therapeutics appoints Hannah Fry as Controller and CEO as principal financial officer after CFO departure

Protara Therapeutics, Inc.

Blaine Davis departed as CFO on July 15, 2022.
Hannah Fry appointed Controller effective July 16, 2022, with $255,000 base salary and 25,000 RSU award.
CEO Jesse Shefferman appointed as principal financial officer of the company.
Fry's severance includes six months base salary and pro-rata equity vesting on certain awards.
Fry previously served as Senior Director, Assistant Controller at Protara.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Blaine Davis

Chief Financial Officer

TARA · Protara Therapeutics, Inc.

Effective: 2022-07-15
Successor: Jesse Shefferman
Filed: July 18, 2022, 7:59 PM ET

Protara Therapeutics, Inc. (the “Company”) announced that Blaine Davis, the Chief Financial Officer of the Company, left the Company to pursue other opportunities on July 15, 2022.

Appointed

Hannah Fry

Controller

TARA · Protara Therapeutics, Inc.

Effective: 2022-07-16
Filed: July 18, 2022, 7:59 PM ET

Effective July 16, 2022 (the “Effective Date”), Hannah Fry has been appointed to the role of Controller of the Company.

Appointed

Jesse Shefferman

principal financial officer

TARA · Protara Therapeutics, Inc.

Effective: 2022-07-16
Filed: July 18, 2022, 7:59 PM ET

Also effective July 16, 2022, Mr. Shefferman has been appointed as principal financial officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Blaine Davis departed as Chief Financial Officer at Protara Therapeutics, Inc..

Action: left
Role: Chief Financial Officer

Exact text from the filing

Protara Therapeutics, Inc. (the “Company”) announced that Blaine Davis, the Chief Financial Officer of the Company, left the Company to pursue other opportunities on July 15, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Hannah Fry was appointed as Controller at Protara Therapeutics, Inc..

Action: appointed
Role: Controller

Exact text from the filing

Effective July 16, 2022 (the “Effective Date”), Hannah Fry has been appointed to the role of Controller of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jesse Shefferman was appointed as principal financial officer at Protara Therapeutics, Inc..

Action: appointed
Role: principal financial officer

Exact text from the filing

Also effective July 16, 2022, Mr. Shefferman has been appointed as principal financial officer of the Company.

View on SEC.gov

Protara Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-039976

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.